LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer

ConclusionsLJM716 was well tolerated in Japanese patients, and a degree of tumor shrinkage was observed.Clinical trial informationClinicalTrials.gov NCT01911936.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research